<DOC>
	<DOCNO>NCT00000960</DOCNO>
	<brief_summary>To determine whether rate HIV transmission mother infant reduce continuous oral zidovudine ( AZT ) treatment HIV infect pregnant woman , intravenous AZT childbirth , oral AZT treatment newborn infant birth six week age . The study also design evaluate safety AZT pregnant woman newborn infant . No method exist prevent transmission HIV infect mother newborn infant . Giving antiviral agent ( AZT ) mother newborn could theory decrease risk infection newborn reduce exposure fetus maternal virus , preventive treatment fetus exposure .</brief_summary>
	<brief_title>The Safety Effectiveness Zidovudine HIV-Infected Pregnant Women Their Infants</brief_title>
	<detailed_description>No method exist prevent transmission HIV infect mother newborn infant . Giving antiviral agent ( AZT ) mother newborn could theory decrease risk infection newborn reduce exposure fetus maternal virus , preventive treatment fetus exposure . Patients enrolled pregnancy , 14 34 week gestation . They choose random selection receive AZT placebo . Treatment continue labor time begin receive continuous intravenous study drug . Study drug treatment discontinue umbilical cord clamp . AZT offer woman per label indication 6 week postpartum , appropriate medical followup arrange . Mothers develop AIDS define illness whose CD4+ cell count decrease le 200 cells/mm3 pregnancy offer open-label drug time . The mother follow primary obstetrician AIDS Clinical Trials Unit ( ACTU ) subunit facility . The mother may deliver ACTU non-ACTU site . Treatment infant start newborn nursery continue outpatient basis . Infants receive study treatment mother 6 week , monitor week 78 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed infant : Treatment sign drug withdrawal ( e.g. , phenobarbital , chlorpromazine , tincture opium , paregoric , Valium ) . Treatment nonserious condition ( e.g. , syphilis treatment , hepatitis B vaccine ) . All essential supportive treatment condition nonlife threaten deem onsite pediatrician . Acetaminophen . Standard immunization . Allowed woman : All medications/treatments require normal OB care HIV+ woman , except noted exclusion . Pneumocystis prophylaxis indicate . Topical steroid . Parenteral oral steroid 6 few day . Concurrent Treatment : Allowed pregnant woman : Blood transfusion anemia ( hemoglobin le 7 g/dl ) . Allowed infant : Blood transfusion anemia except attribute study drug . Patients must : Have HIV infection . Intend carry pregnancy term . Be willing follow participate ACTG center duration study . Be able provide inform consent ( available , father fetus must also provide informed consent ) . Infants may enroll simultaneously pediatric protocol complete initial 6 week study treatment . Inclusion age woman 13 year old IRB local age consent . Inclusion age infant 0 20 month . Exclusion Criteria Coexisting Condition : Infants follow condition symptom exclude : Requiring treatment hyperbilirubinemia ( except phototherapy ) . Concurrent Medication : Excluded : Infants : Antiretroviral drug vaccine . Excluded current pregnancy : Zidovudine ( AZT ) . Other antiretroviral agent ( e.g. , rCD4 , CD4IgG , d4T , didanosine ( ddI ) , dideoxycytidine ( ddC ) ) , passive immunotherapy ( e.g. , HIVIG ) , antiHIV vaccine , cytolytic chemotherapeutic agent . Corticosteroids equal 7 day . Patients follow exclude : Evidence preexist fetal anomaly may ( 1 ) result high probability fetus/infant survive end study period ( e.g. , anencephaly , renal agenesis , Potter 's syndrome ) ; ( 2 ) increase fetal tissue concentration zidovudine ( AZT ) metabolites toxic level ( e.g. , neural tube ventral wall defect ) . Baseline sonogram complete within 28 day prior randomization demonstrate 2nd trimester finding anencephaly oligohydramnios , 3rd trimester finding unexplained polyhydramnios , fetal hydrops , ascites evidence preexist inutero anemia . History intolerance AZT dose 500 less mg/day prior pregnancy result discontinuation treatment 4 week . Recipient AZT current pregnancy indication meet criterion AZT define protocol ( CD4+ cell count less 200 cells/mm3 AIDS ) . Infants parent/guardian available give inform consent necessary . Prior Treatment : Excluded current pregnancy : Radiation therapy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Pregnancy</keyword>
	<keyword>Pregnancy Complications , Infectious</keyword>
	<keyword>Prenatal Exposure Delayed Effects</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>